Bicycle Therapeutics (NASDAQ:BCYC) Reaches New 52-Week Low – Time to Sell?

Bicycle Therapeutics plc (NASDAQ:BCYC)’s share price reached a new 52-week low during trading on Friday . The company traded as low as $12.17 and last traded at $12.21, with a volume of 152520 shares. The stock had previously closed at $12.61.

Wall Street Analysts Forecast Growth

Several analysts have issued reports on BCYC shares. HC Wainwright reissued a “buy” rating and set a $33.00 target price on shares of Bicycle Therapeutics in a research note on Monday, January 13th. B. Riley reduced their price objective on Bicycle Therapeutics from $28.00 to $17.00 and set a “neutral” rating for the company in a research note on Friday, December 13th. Needham & Company LLC reaffirmed a “buy” rating and set a $32.00 target price on shares of Bicycle Therapeutics in a research note on Monday, January 13th. Royal Bank of Canada reissued an “outperform” rating and issued a $35.00 price target on shares of Bicycle Therapeutics in a research report on Friday, November 1st. Finally, JMP Securities dropped their price objective on shares of Bicycle Therapeutics from $32.00 to $26.00 and set a “market outperform” rating on the stock in a research note on Wednesday, December 18th. Two investment analysts have rated the stock with a hold rating and seven have issued a buy rating to the stock. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average target price of $33.25.

Bicycle Therapeutics Stock Performance

The company has a market capitalization of $841.03 million, a P/E ratio of -3.70 and a beta of 0.93. The company has a 50-day simple moving average of $15.22 and a 200 day simple moving average of $20.65.

Insider Transactions at Bicycle Therapeutics

In other news, COO Alistair Milnes sold 4,578 shares of Bicycle Therapeutics stock in a transaction that occurred on Thursday, January 2nd. The shares were sold at an average price of $14.09, for a total value of $64,504.02. Following the completion of the transaction, the chief operating officer now owns 100,724 shares in the company, valued at approximately $1,419,201.16. The trade was a 4.35 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, insider Santiago Arroyo sold 4,943 shares of the stock in a transaction on Thursday, January 2nd. The stock was sold at an average price of $14.09, for a total value of $69,646.87. Following the sale, the insider now owns 69,057 shares in the company, valued at $973,013.13. The trade was a 6.68 % decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 33,933 shares of company stock worth $549,501. 8.50% of the stock is currently owned by company insiders.

Institutional Trading of Bicycle Therapeutics

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in BCYC. Assetmark Inc. acquired a new position in Bicycle Therapeutics in the third quarter valued at about $34,000. GAMMA Investing LLC boosted its stake in Bicycle Therapeutics by 105.1% during the 3rd quarter. GAMMA Investing LLC now owns 2,026 shares of the company’s stock worth $46,000 after acquiring an additional 1,038 shares during the last quarter. Avior Wealth Management LLC acquired a new position in Bicycle Therapeutics during the fourth quarter valued at approximately $57,000. China Universal Asset Management Co. Ltd. raised its holdings in Bicycle Therapeutics by 30.7% in the fourth quarter. China Universal Asset Management Co. Ltd. now owns 9,329 shares of the company’s stock worth $131,000 after purchasing an additional 2,191 shares during the period. Finally, JPMorgan Chase & Co. raised its stake in Bicycle Therapeutics by 26.8% during the 3rd quarter. JPMorgan Chase & Co. now owns 8,424 shares of the company’s stock worth $191,000 after buying an additional 1,782 shares during the period. 86.15% of the stock is currently owned by institutional investors and hedge funds.

Bicycle Therapeutics Company Profile

Bicycle Therapeutics plc, a clinical-stage biopharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics in the United States and the United Kingdom. Its product pipeline comprising BT8009, a bicycle toxin conjugate (BTC) which is in phase I/II/III clinical trial for the treatment of high nectin-4 expressing tumors; BT5528, a BTC which is in phase I/II clinical trial for the treatment of Ephrin type A receptor 2 expressing tumor; BT7480, a Bicycle TICA molecule which is in phase I/II targeting Nectin-4 and agonizing CD137; and BT7455, a Bicycle TICA molecule targeting Ephrin type A receptor 2 and CD137 and is in preclinical trial.